Back

The Influence of post-implant antithrombotic drug therapy on the incidence of device thrombus and stroke in the AMULET-Registry Study

19 June 2017 (08:30 - 08:40)
Organised by:
Congress Presentation Part of: Late Breaking Trial Session - Left atrial appendage occlusion Automatic implantable cardioverter / defibrillator EHRA Premium Access EHRA EUROPACE - CARDIOSTIM 2017

About the speaker

Photo
Doctor Boris Schmidt

Cardioangiologisches Centrum Bethanien, Frankfurt (Germany)

2 More presentations in this session

Presentation thumbnail
Professor L. Fauchier (Tours, FR)
Slides Video
Presentation thumbnail
Video

Access the full session

Session thumbnail
Late Breaking Trial Session - Left atrial appendage occlusion

The Event

Event poster

EHRA EUROPACE - CARDIOSTIM 2017

19 June 2017 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Interventional left atrial appendage occlusion is effective and safe in high-risk patients with prior stroke: comprehensive insights from the multicenter German LAARGE registry
26 August 2023
thumbnail
Congress Session
Optimal implantation technique for PM and ICD
16 April 2023
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
26 August 2023
thumbnail
Congress Presentation
Reduction of major adverse and major cardiovascular events in patients with atrial fibrillation and stent implantation treated with left atrial occlusion device vs oral anticoagulants strategy.
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources